The Role of Genetic Factors in the Development of Arterial Hypertension in the Kazakh Population

Preventive and Personalized Medicine (2021-2023)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05088486

Enrollment

1200

Registered

2021-10-22

Start date

2022-03-30

Completion date

2023-01-20

Last updated

2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Hypertension

Keywords

GWAS

Brief summary

This is a GWAS study that aims to identify possible candidate genes associate to arterial hypertension by exploring single nucleotide polymorphism (SNP) in a group of arterial hypertension, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with arterial hypertension

Detailed description

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Interventions

GENETICDNA analysis

GWAS

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Inclusion criteria

* Persons with confirmed arterial hypertension; * The age of patients is from 18 to 55 years old inclusive; * Persons of Kazakh nationality, whose paternal and maternal grandparents identify themselves as Kazakhs; * Persons who are able and willing to provide written informed consent; * Persons capable and willing to comply with the research protocol;

Exclusion criteria

* Persons under 18 and over 55; * Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent; * Pregnant or lactating women; * Tuberculosis of any localization in the active phase and in history; * Severe and decompensated diseases of the liver and kidneys, cardiovascular system; * Severe and decompensated course of endocrine diseases; * Autoimmune diseases; * Systemic diseases; * Cancer.

Design outcomes

Primary

Measure	Time frame	Description
number of SNPs associated with arterial hypertension	1 year	Using GWAS to identify candidate genes associate with arterial hypertension

Countries

Kazakhstan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026